what if i miss my semaglutide dose Missed Dose: to Do Next What Side Effects to Expect

Week 4 benchmarks (still at 0.25 mg) Below average: Less than 1 percent body weight loss

In individuals with overweight or obesity and type 2 diabetes, semaglutide 2.4 mg resulted in a mean weight loss of 9.6% compared to 3.4% with placebo in 68 weeks

Smaller, frequent meals prevent the overfullness that can trigger nausea

Wegovy tablets and injections are FDA-approved in adults for: weight loss and weight management in adults with obesity or adults who are overweight and have a weight-related medical problem (e.g., blood pressure, type 2 diabetes, or high cholesterol) reducing major cardiovascular event risks (such as heart attack, stroke, or death) in adults with established CV disease and either obesity or overweight Wegovy injection is also FDA-approved for: weight loss and weight management patients with obesity who are 12 years and older non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), this is an accelerated approval

The findings indicated an increase in the relative incidence of NAION among semaglutide users compared to those not exposed to the drug